PARSIPPANY, N.J. / Jan 18, 2024 / Business Wire / Zoetis Inc. (NYSE:ZTS) has been selected as a 2024 Catalyst Award recipient for its global initiative, Awareness and Action Drives Impact, that is advancing equity for women and other underrepresented groups across the company — from the frontlines to senior leadership. Zoetis is one of only two organizations receiving this global award and is the first animal health company to be recognized.
“We are truly honored to receive the 2024 Catalyst Award for our global DE&I initiatives,” said Kristin Peck, CEO of Zoetis. “At Zoetis, we embrace differences through intentional efforts that drive equity and belonging. Our DE&I efforts will only continue as we keep building a welcoming workplace and animal health industry that celebrates uniqueness – and enables us to make a positive impact on the lives of our colleagues and those who care for animals.”
Highlights that Catalyst featured as part of Zoetis’ recognition include:
As a result of Zoetis’ global initiative, between 2020-2023 women’s global representation increased from 47% to 50% among senior and mid-level colleagues, and 44% to 49% (5 percentage points) in other levels of the organization, including frontline colleagues in manufacturing and sales. On the Board of Directors, women’s overall representation increased from 36% to 42% (6 percentage points), and the representation of women from marginalized racial and ethnic groups increased from 9% to 17% (8 percentage points).
Zoetis participated in a rigorous examination by Catalyst of the company’s talent, diversity, equity and inclusion initiatives requiring the company to show proven, measurable results that benefit women across a range of dimensions. This was followed by intensive on-site interviews to hear directly from colleagues about their experiences at Zoetis as a result of the multi-year, multi-faceted global initiative.
Zoetis will be honored at the Catalyst Awards Conference & Gala on Tuesday, March 12, in New York City. This year’s theme, The Catalyst Effect, celebrates the collective impact of individuals committed to diversity, equity, and inclusion — who together can create massive change.
Learn more
To learn more about Zoetis’ award-winning culture, visit www.zoetis.com/join-us. More information about the 2024 Catalyst Award can be found here.
About Zoetis
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.1 billion in 2022 with approximately 13,800 employees. For more information, visit www.zoetis.com.
About Catalyst
Catalyst is a global nonprofit supported by many of the world’s most powerful CEOs and leading companies to help build workplaces that work for women. Founded in 1962, Catalyst drives change with preeminent thought leadership, actionable solutions, and a galvanized community of multinational corporations to accelerate and advance women into leadership—because progress for women is progress for everyone.
Since 1987, Catalyst has recognized 108 innovative and pioneering initiatives at 96 organizations from around the world. Catalyst Award Winners lead a community of forward-thinking organizations that are developing new and impactful ways to advance gender equity in the workplace.
Last Trade: | US$189.23 |
Daily Change: | 2.64 1.41 |
Daily Volume: | 1,935,370 |
Market Cap: | US$85.730B |
August 06, 2024 May 02, 2024 February 13, 2024 November 02, 2023 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB